Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Inclusion Criteria:

   - The subject has a cytologically or histologically and radiologically confirmed,
   advanced, recurrent, or metastatic solid tumor of the nine types listed below:

      - Pancreatic Cancer

      - Castration-Resistant Prostate Cancer (CRPC)

      - Hepatocellular Carcinoma (HCC)

      - Gastric or Gastroesophageal Junction Cancer

      - Melanoma

      - Small Cell Lung Cancer (SCLC)

      - Ovarian cancer, primary peritoneal or fallopian tube carcinoma

      - Breast cancer that is one of the following subtypes: estrogen receptor positive
      breast cancer, estrogen receptor/progesterone receptor/HER2-negative
      (triple-negative), or inflammatory (regardless of receptor status) disease
      histology

      - Non-Small Cell Lung Cancer (NSCLC)

   - Certain requirements for prior therapies may apply

   - The subject has documented progressive disease at screening

   - Subjects having any tumor type of other than CRPC must have at least one lesion that
   is not within a previously irradiated field and is measurable on CT or MRI scan

   - The subject has recovered to baseline or CTCAE ≤ Grade 1 from toxicities related to
   prior treatment (some exceptions apply)

   - The subject is ≥ 18 years old on the day of consent

   - Tissue samples from archival or fresh tissue, or a tissue block of the subject's tumor

   - The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
   or 1

   - The subject has adequate organ function

   - The subject is capable of understanding and complying with the protocol requirements
   and has signed the informed consent document

   - Sexually active fertile subjects (male and female), and their partners, must agree to
   use medically accepted methods of contraception during the course of the study and for
   3 months after the last dose of the study drug(s)

   - Female subjects of childbearing potential must have a negative pregnancy test at
   screening

Exclusion Criteria:

   - The subject has experienced clinically-significant hematemesis or hemoptysis of >0.5
   teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3
   months before the first dose of study treatment

   - The subject has a cavitating pulmonary lesion(s) or a pulmonary lesion abutting or
   encasing a major blood vessel

   - Certain restrictions on prior treatments apply

   - The subject has received drugs used to control loss of bone mass within 4 weeks prior
   to the first dose of study treatment

   - The subject has known symptomatic or uncontrolled brain metastases or epidural disease

   - The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial
   thromboplastin time (PTT) test results that are above (1.3x)the laboratory upper limit
   of normal

   - The subject has a corrected QT interval(QTcF)>500 ms at screening

   - The subject requires concomitant treatment, in therapeutic doses, with anticoagulants
   such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and
   antiplatelet agents (low-dose aspirin (≤81 mg/day), low-dose warfarin (≤1mg/day, and
   prophylactic low molecular weight heparin (LMWH) are permitted)

   - The subject has uncontrolled, significant intercurrent illness

   - The subject is unable to swallow capsules

   - The subject is pregnant or breastfeeding

   - The subject has a previously-identified allergy or hypersensitivity to components of
   the study treatment formulation

   - The subject is unable or unwilling to abide by the study protocol or cooperate fully
   with the investigator or designee

   - The subject has had another diagnosis of malignancy requiring systemic treatment
   within the last two years, unless non-melanoma skin cancer, in-situ carcinoma of the
   cervix, or superficial bladder cancer